Telomelysin

Drug Profile

Telomelysin

Alternative Names: hTERT-Ad; OBP-301; Telomelysin

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Oncolys Biopharma
  • Developer Okayama University; Oncolys BioPharma
  • Class Antineoplastics; Oncolytic viruses; Viral proteins
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Head and neck cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Oesophageal cancer
  • Preclinical Adenocarcinoma; Neuroblastoma
  • No development reported Breast cancer; Mesothelioma; Osteosarcoma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 31 Aug 2016 Oncolys and National Cancer Center Hospital East plans a clinical trial in Cancer (Combination therapy) in Japan
  • 31 Aug 2016 Oncolys BioPharma submits a phase II clinical trial protocol to the US FDA for malignant melanoma
  • 05 Jul 2016 Onoclys BioPharma and Nagoya University agree to co-develop telomelysin in Japan for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top